We are Attending the OPT Congress
March 5, 2025
OPT Congress
We’re excited to attend OPT Boston 2025!
This is a major event for those working at the frontline of oligonucleotide and mRNA therapeutics, occurring on 11th and 12th of March, 2025. Come and discuss 3R and NAM compliant drug development with our amazing team. We will share insights on how ID.Flow® can support you in efficacy, safety and FIH dose prediction.
Swing by our poster, abstract below:
“Prediction of clinical immunotoxicity of oligonucleotide therapeutics using an ex vivo test system with circulating human whole blood”
Limitations in commonly used immunotoxicity models, such as NHPs, lead to less relevant assessments of human responses to oligonucleotides (ONDs). Here, the immunotoxicity of two FDA-approved ONDs, imetelstat and inotersen, was investigated in ID.Flow®, a physiologically relevant ex vivo test system using fresh, minimally manipulated human whole blood. Results confirmed that ID.Flow® can predict immunotoxic responses to both drugs, including effects on cells, cytokines, and complement, mimicking clinically observed responses.
Don’t miss this opportunity to connect, our team will be in the Boston area 10-13 of March. Don´t miss the chance and meet us!
Book a meeting and contact us here: https://immuneed.com/contact/